ArticleFrontiers in endocrinology2025
Impact of pre-therapeutic fasting plasma glucose on survival outcomes in advanced non-small cell lung cancer patients.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The necessity of tight glycemic management in non-small cell lung cancer (NSCLC) remains controversial. This study aimed to determine whether baseline fasting plasma glucose (FPG) levels could serve as an independent prognostic marker for survival outcomes in advanced NSCLC. Patients and methods: This study included 960 patients with advanced NSCLC, who were categorized into low (< 3.9 mmol/L), normal (3.9-6.1 mmol/L), and high FPG groups (> 6.1 mmol/L) based on pre-treatment FPG levels. The analyzed covariates included demographics, clinical characteristics, oncogenic mutation status, and first-line treatments. Survival curves with log-rank tests were estimated to compare survival differences between groups. Univariate and multivariate Cox proportional hazards regression were performed to investigate the prognostic factors. Furthermore, smooth curve fitting and piecewise Cox regression were used to explore the non-linear relationships between FPG and mortality risk, while subgroup analyses were employed to test interactions. Results: Both low (12.0 Conclusion: Abnormal FPG levels are independent risk factors for the long-term prognosis of advanced NSCLC. Further prospective multicenter studies are needed to confirm these associations and clarify whether glycemic assessment and management influence survival outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.